Cargando…

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents

Global concern has been raised by the emergence and rapid transmission of the heavily mutated SARS-CoV-2 Omicron variant (B.1.1.529). So far, the infection features and immune escape ability of the Omicron variant have not been extensively studied. Here, we produced the Omicron pseudovirus and compa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Chengbao, Chen, Xianying, Mei, Fanghua, Xiong, Qing, Liu, Qianyun, Dong, Lianghui, Liu, Chen, Zou, Wenjing, Zhan, Faxian, Hu, Bing, Liu, Yingle, Liu, Fang, Zhou, Li, Xu, Junqiang, Jiang, Yongzhong, Xu, Ke, Cai, Kun, Chen, Yu, Yan, Huan, Lan, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856021/ https://www.ncbi.nlm.nih.gov/pubmed/35060426 http://dx.doi.org/10.1080/22221751.2022.2031311

Ejemplares similares

Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China
por: Liu, Qianyun, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
por: Ai, Jingwen, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination
por: Wang, Miao, et al.
Publicado: (2022)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave
por: Lu, Guanzhu, et al.
Publicado: (2022)

Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study
por: Chen, Xiaohua, et al.
Publicado: (2022)

Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas
por: Jia, Hongling, et al.
Publicado: (2022)

Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China
por: Zheng, Liwei, et al.
Publicado: (2023)

A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China
por: Lin, Mengna, et al.
Publicado: (2023)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Omicron: a drug developer’s perspective
por: Fang, Fang “Flora”, et al.
Publicado: (2022)

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants
por: de La Vega, Marc-Antoine, et al.
Publicado: (2023)

Intranasal infection by SARS-CoV-2 Omicron variants can induce inflammatory brain damage in newly weaned hamsters
por: Li, Can, et al.
Publicado: (2023)

Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort
por: Ma, Ensi, et al.
Publicado: (2022)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)
por: Wang, Hongyu, et al.
Publicado: (2023)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
por: Zhang, Xiaqing, et al.
Publicado: (2023)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
por: Liu, Shuo, et al.
Publicado: (2023)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
por: Hu, Bingjie, et al.
Publicado: (2022)

A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity
por: Li, Yang, et al.
Publicado: (2022)

Effectiveness of vaccination in reducing hospitalization and mortality rates in dialysis patients with Omicron infection in China: A single-center study
por: Zhang, Quanchao, et al.
Publicado: (2023)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study
por: Cao, Cheng, et al.
Publicado: (2023)

A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China
por: Cai, Jianpeng, et al.
Publicado: (2023)

Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review
por: Paul, Pradipta, et al.
Publicado: (2023)

Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
por: Xu, Hongqin, et al.
Publicado: (2023)

Hybrid immunity and protection against infection during the Omicron wave in Malta
por: Cauchi, John Paul, et al.
Publicado: (2023)

Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants
por: Yan, Qihong, et al.
Publicado: (2022)

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
por: Chen, Xinhua, et al.
Publicado: (2022)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
por: Wu, Qianhui, et al.
Publicado: (2023)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong
por: Poon, Rosana Wing-Shan, et al.
Publicado: (2022)

The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants
por: Chen, Yuxin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3s4tqluafadbue5b1n3o5j13ur